GovChime
Notice ID: ebdf499f4dd0429a9a08c2b4a2fa4759Award NoticeAwardedArchived

6505--Dallas Pharmacy Compounding Oncology NTX VA Healthcare System

Awarded on October 28, 2025. Full description on SAM.gov.

Awarded tounder 36C25726D002436C25726N0098 (source: SAM.gov award notice)• $1.2M

Overview

Posted
October 28, 2025
Notice type
Award Notice
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Veterans Affairs

Notice details

Office
257-NETWORK CONTRACT OFFICE 17 (36C257)
Place of performance
Department of Veterans Affairs North Texas Veterans Healthcare System, Dallas, TX, 75216
Last updated
Nov 6, 2026
First published
Last updated on SAM.gov
Award date
Oct 28, 2025
Award amount (SAM.gov award notice)
$1.2M

Identifiers

Solicitation number
36C25726Q0033
Notice ID
ebdf499f4dd0429a9a08c2b4a2fa4759
Award number (PIID)
36C25726D002436C25726N0098

Description

Dallas VA Pharmacy Compounding for Oncology Medications

Full description on SAM.gov

Award Overview

Award Number

36C25726D002436C25726N0098

Award Amount (SAM.gov award notice)

$1.2M

Award Date

Oct 28, 2025

Awardee

Awardee UEI

RN5UVE9XMJN4

Awardee CAGE Code

9HGM2

Awardee Address

CHANDLER, AZ 85224, AZERBAIJAN

Line Item Number

1

Original Solicitation

Notice ID: ebdf499f4dd0429a9a08c2b4a2fa4759

Posted Date: Oct 28, 2025

Original Response Deadline: Not specified

Contract Details

Contract data not yet available

Contract details typically appear within 2-4 weeks after award; DoD awards are published about 90 days after signature.

Contacts

Contracting Officer

Primary Contact

Jennifer Stringer
Contracting Officer

Documents

Files (3)

  • VA Pricing June 1 2025.xlsx

    42 KBAdded in Combined Synopsis/Solicitation version 4Posted
    Download
  • 36C25726D0024 36C25726N0098_1.docx

    14 KBAdded in Award Notice version 6Posted
    Download
  • 36C25726Q0033_1.docx

    144 KBAdded in Combined Synopsis/Solicitation version 4Posted
    Download

Lifecycle

  1. 4
    Version 4Combined Synopsis/SolicitationArchived

    Q517--Dallas Pharmacy Compounding-Oncology

    Notice 92e4d26abfe3457bac92b97350accfae on SAM.gov

  2. 6
    Version 6Award NoticeArchivedCurrent

    Type changed from Combined Synopsis/Solicitation to Award Notice

    6505--Dallas Pharmacy Compounding Oncology NTX VA Healthcare System

    Notice ebdf499f4dd0429a9a08c2b4a2fa4759 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
THIS REQUEST FOR INFORMATION (RFI) / SOURCES SOUGHT NOTICE IS ISSUED SOLELY FOR INFORMATION AND PLANNING PURPOSES. THIS IS NOT A SOLICITATION. SUBMISSION OF INFORMATION ABOUT PRICING, DELIVERY, THE MARKET, AND CAPABILITIES IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS RFI FOR PLANNING PURPOSES IN ACCORDANCE WITH (IAW) FAR 15.201(e). DISCLAIMER This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. IAW FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. SOURCES SOUGHT/RFI DESCRIPTION This is NOT a solicitation announcement. This is a Sources Sought Notice / RFI only. The purpose of this Sources Sought Notice / RFI is to gain information about potential qualified sources and their size classification relative to NAICS 325412 (size standard of 1,300 Employees). Responses to this Sources Sought Notice / RFI will be used by the Government to make appropriate acquisition decisions. After review of the responses to this Sources Sought Notice / RFI, further RFIs and/or a solicitation or other announcements may be published. STATEMENT OF WORK Manufacturing and delivery of sterile/aseptic, USP 825 compliant, low enriched uranium (LEU) radiopharmaceuticals for diagnosis and treatment of patients receiving services at VA San Diego Healthcare System Nuclear Medicine Service. Delivery services must meet all DOT requirements for shipment and delivery of radioactive drugs. Stat delivery services (within 1 hour) must be available 24hrs/day 365 days/year. Companies providing services must provide dose labels compatible with the Nuclear Medicine information System (NMIS) computerized radiopharmacy database. Companies must provide storage, preparation, labeling and delivery of research radiopharmaceuticals as requested. Base January 1, 2027, through December 31, 2027 OY 1 January 1, 2028, through December 31, 2028 OY 2 January 1, 2029, through December 31, 2029 OY 3 January 1, 2030, through December 31, 2030 OY 4 January 1, 2031, through December 31, 2031 PARTICIPATING VA HEALTHCARE SYSTEMS: VA San Diego Healthcare System 3350 La Jolla Village Drive Nuclear Medicine Service San Diego, CA 92161 2. ROUTINE ORDERS Routine orders require delivery the next business day, unless specified elsewhere in this contract. 3. EMERGENCY ORDERS Stat delivery services (within 1 hour) must be available 24hrs/day 365 days/year. 4. PRICE/COST SCHEDULE Description Estimated Min Quantity UOM Unit Price I-123 USP NaI 200 uCi capsules 35 EA I-123 USP NaI 2 mCi 3 EA I-123 USP NaI 4 mCi 3 EA I-123 Iobenguane Sulfate (I-123 Adreview MIBG) 1 I-131 USP NaI DX cap per mCi (4mci) 10 EA I-131 USP NaI TX cap per mCi (150mci) 10 EA In-111 Pentetreotide (Octertide/Octeoscan) UD 1 EA In-111 Pentetate (DTPA) SDV/Vial 1 EA In-111 Autologuous WBCs tagging, pick-up and delivery 9 EA In-111 WBC Blood Kit (Heparin) 9 EA 99mTc Mertiatide (MAG3) UD 38 EA 99mTc Sulfur colloid UD ( Filtered ) 10 EA 99mTc Sulfur colloid UD 90 EA 99mTc Macro Aggregated Albumin (MAA) UD 220 EA 99m Tc High Concentrated (Technegas) 25mCi 150 EA 99m Tc Pentetate (DTPA)UD 1 EA 99mTc dimercaptosuccinic acid (DMSA) UD 1 EA 99mTc Medronate (MDP) UD 300 EA 99mTc Sestamibi (Cardiolite®) UD DO NOT SUBSTITUTE 3400 EA 99mTc PYP or (HDP) 50 EA 99mTc NaTco4 UD per mCi 30 EA 99mTc Mebrofenin (Choletec)UD 25 EA Tl-201 Thallious Chloride UD 1 EA Ga-67 Gallium Citrate UD 1 EA GA-68 DOTATATE (NET-SPOT) 15 EA Macro Aggregated Albumin Vial 0 Pentetate Vial 0 EA Medronate Vial 0 EA Ultra-tag kit 4 Hep-lock for RBC Tag 4 Standard scheduled delivery 3-4 per/day  Stat Delivery Service (within 1 hour) available 24 hours/day 8 After hours call out 4 Heparin vial 4 Heparin/Hetastarch Syringe 9 TOTAL 5. DELIVERY LOCATION, NORMAL WORK HOURS AND INSTRUCTIONS: Delivery Location Nuclear Medicine Service, Main Hospital, 4 West, 4th Floor Normal Work Hours 7:00am to 4:00pm, Monday through Friday 6. PACKAGING AND MARKING a) The contractor shall package, mark and transfer all radioactive material in accordance with all applicable local, state, and federal regulations. b) Items must be properly packaged to prevent damage during shipping, handling, and storage. c) All outer packages must contain the complete purchase number, obligation number and contract number in addition to the shipping address. The purchase number and obligation number will be provided by the individual at the time of ordering. The contract number will be provided upon notice of contract award. d) Packaging List: A packing list/slip shall be enclosed with each shipment indicating the purchase/obligation and delivery order number, contract number, items/quality ordered, and items/quality shipped. 7. RECALLED AND DEFECTIVE PRODUCTS The Contractor will immediately notify the Contracting Officer of any recalls of product or other important product safety issues. As appropriate, the Contractor will replace and/or reimburse recalled / defective products at no cost to the Government. The Contractor may be liable for costs of processing recalls, i.e. administrative and clinical services to replace recalled / defective products. 8. SAFETY GUIDELINES AND REQUIREMENTS The Contractor shall perform all functions of the contract in compliance with Occupational Safety and Health Administration (OSHA), FDA, NRC, Joint Commission safety guidelines and Department of Transportation (DOT) requirements. The Contractor shall self-report any violations to the point of contact (POC) within twenty-four (24) hours. Delivery personnel shall be trained in Radiation Safety Techniques, Nuclear Regulatory Commission, Joint Commission safety guidelines and Department of Transportation requirements. 9. NATIONAL HOLIDAYS OBSERVED BY THE GOVERNMENT New Year s Day January 1 Martin Luther King s Birthday 3rd Monday in January Presidents Day 3rd Monday in February Memorial Day Last Monday in May Juneteenth June 19 Independence Day July 4 Labor Day 1st Monday in September Columbus Day 2nd Monday in October Veterans Day November 11 Thanksgiving Day 4th Thursday in November Christmas Day December 25th The President of the United States of America may declare additional days as a federal holiday, and if so, this holiday will automatically be added to the list above. When a holiday falls on a Sunday, the following Monday shall be observed as a Federal holiday. When a holiday falls on a Saturday, the preceding Friday shall be observed as a Federal Holiday. 10. CONTRACTOR DELIVERY PERSONNEL All contractor personnel are required to wear clothing bearing the name of the Contractor and wear a badge that has the Contractor name. Contractor personnel must have a picture I.D. and must be able to speak English. 11. PARKING AND SPEED LIMIT Park only in areas designated by the Contracting Officer Representative (COR) or otherwise directed by Police and Security Service personnel. The Contractor shall display on each of its vehicles the company name in a size that is clearly visible. Upon receipt of award, the Contractor shall submit a list of employees and vehicles to the COR of each facility. The Contractor shall conform to the speed limit set at each Government facility. Should Contractor personnel receive a citation for parking, speeding or other infraction from VA Security, the offenses will be handled in Federal Court as they are Federal offenses. 12. INVOICE AND PAYMENT No advanced payments will be authorized. The contractor shall submit invoices monthly. The invoice must have at a minimum, the contract number, assigned purchase order, assigned obligation number, date order was placed, date order was shipped, and any additional necessary detailed information to identify service rendered. Payment on invoice may be delayed in invoice(s) are not completed properly. NOTE: Potential quoters must be aware that the items being acquired are procured as Brand Name or Equal. For those items that are or equal , a description of the salient characteristics is outlined below. It is quoter s responsibility to demonstrate its quote meeting the salient physical and functional characteristics included in this solicitation. If the quote does NOT demonstrate, the offer will be considered non-responsive. The interested parties bear full responsibility to ensure their submission demonstrates to the government that they can satisfy the requirement by providing the brand name or equal to the supplies being requested. VAAR 852.212-71 Gray Market and Counterfeit Items clause applies on this acquisition. No remanufacturers or gray market items will be acceptable. Vendor shall be an Original Equipment Manufacturer (OEM), authorized dealer, authorized distributor or authorized reseller verified by an authorization letter or other documents from the OEM signed. The letter must either state specific product(s) quoted or that the quoter is an authorized distributor for all the manufacturer s products. This letter must be on the manufacturer s letterhead and contains the signature of an authorized official for the manufacturer. If the interested contractor fails to provide a signed letter from the OEM (unless the contractor is the OEM), the contractor s response will be deemed non-responsive and will not be considered for award. The list of DRAFT characteristics is intended to be descriptive, not restrictive, of the supplies/services that are required. If your company is interested and capable of providing the required supplies/services, please provide the information indicated below. Response to this notice should include company name, address, point of contact, size of business pursuant to the following questions: (1) Submit your capabilities statement illustrating how your organization can/cannot meet the list of SOW requirements. For instances where your company cannot meet the SOW requirement(s), please explain. For instances where your company can meet the SOW requirement(s), please show how your company meets/exceeds each requirement. (2) Please review the list of SOW requirements and provide any additional feedback or suggestions. If none, please reply as N/A. (3) Please indicate the size status and representations of your business, such as but not limited to: Service-Disabled Veteran-Owned Small Business (SDVOSB), Veteran-Owned Small Business (VOSB), HUBZone, Woman Owned Small Business (WOSB), Large Business, etc. (4) Is your company considered small under the NAICS code identified in this RFI? (5) Are you the manufacturer, authorized distributor, and/or can your company provide a solution to the required supplies/services described in the list of SOW? (6) If you are a large business, do you have any designated/authorized distributors? If so, please provide their company name, telephone, point of contact and size status (if available). (7) If you re a small business and you are an authorized distributor/reseller for the items identified above, do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified. (8) Limitations on Subcontracting: How does your business ensure compliance with the limitations on subcontracting as outlined in 13 CFR § 125.6? (9) Are the items you are identifying/providing considered Commercial of the Shelf (COTS) items as defined in FAR Part 2.101 under commercial items? (10) Non-Manufacturer Rule: If applicable, can you confirm your business complies with the Non-Manufacturer rule? Specifically, does your company: Provide a product from a small business manufacturer or processor? Not exceed 500 employees? Primarily engage in the retail or wholesale trade and normally sell the type of item being supplied? Take ownership or possession of the item(s) with its personnel, equipment or facilities in a manner consistent with industry practice? (11) Please indicate whether your product conforms to the requirements of the Buy American Act? (12) Does your company have a Federal Supply Schedule (FSS) GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract? If so, please provide the contract number(s). (13) If you are an FSS GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract holder, are all the items/solutions you are providing information about available on your schedule/contract? Please state if all or some items are available on the contract. (14) General pricing of your products/solution is encouraged. Pricing will be used for the purpose of market research only. It will not be used to evaluate for any type of award. (15) Please provide your SAM.gov Unique Entity ID/Cage Code number. Responses to this notice shall be submitted via email to Adrienne.Brown4@va.gov. Telephone responses will not be accepted. Responses must be received no later than Friday, November 6, 2026, by 10AM Mountain Time. All responses to this Sources Sought/RFI will be used for planning purposes only. Responses to this Sources Sought Notice / RFI are not considered a request to be added to a prospective bidders list or to receive a copy of the solicitation. If further RFIs and/or a solicitation or other announcement is issued as a result of the information provided from this RFI, all interested parties must respond to the specific posting separately IAW the specifications of that announcement.
85%
Market Research11/06/2026
Emergency Pharmacy Order of DigiFAB
74%
Sole Source / J&AOpen
Sources Sought Notice The Department of Veterans Affairs, Network Contracting Office (NCO) 17, is seeking sources for the following procurement: NETSPOT® Gallium Ga 68 Dotatate Injection Item (radiopharmaceutical) will be delivered to the VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216-7167. NCO 17 is seeking sources from firms that are capable of providing this item. Firms that can provide this item are encouraged to respond to the sources sought notice by contacting the point of contact. Capable firms must respond to the POC before the closing date and time of the notice to be considered. Capable firms must identify with their company name and are encouraged to provide a capabilities statement (if readily available) with their response. This notice is NOT a formal request for quote or proposals. No formal solicitation document exists at this time. The information in this notice is for information and planning purposes only and is not to be construed as a commitment by the government. No contract will be awarded from this notice.
73%
Special Notice10/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
68%
Solicitation11/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
68%
Solicitation12/07/2026

Additional Details

Solicitation Number

36C25726Q0033

Archive Date

Nov 12, 2025

Office Address

San Antonio, TX, 78240